{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:47:06Z","timestamp":1777956426647,"version":"3.51.4"},"reference-count":90,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgpath.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Pathology Clinics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.path.2026.01.007","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:06:46Z","timestamp":1773889606000},"page":"309-321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular Pathology of Genitourinary Tumors"],"prefix":"10.1016","volume":"19","author":[{"given":"Alessia","family":"Cimadamore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Lopez-Beltran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"Montironi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.path.2026.01.007_bib1","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 world Health Organization classification of tumours of the urinary System and Male genital Organs\u2014Part A: renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.path.2026.01.007_bib2","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41379-021-00737-6","article-title":"Novel, emerging and provisional renal entities: the Genitourinary Pathology Society (GUPS) update on renal neoplasia","volume":"34","author":"Trpkov","year":"2021","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.path.2026.01.007_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive molecular characterization of papillary renal-cell carcinoma","volume":"374","author":"Cancer Genome Atlas Research","year":"2016","journal-title":"NEJM"},{"issue":"9","key":"10.1016\/j.path.2026.01.007_bib4","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/jamaoncol.2018.1986","article-title":"Prevalence of germline mutations in cancer susceptibility genes in patients with advanced renal cell carcinoma","volume":"4","author":"Carlo","year":"2018","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.path.2026.01.007_bib5","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00345-018-2288-5","article-title":"Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management","volume":"36","author":"Maher","year":"2018","journal-title":"World J Urol"},{"issue":"6","key":"10.1016\/j.path.2026.01.007_bib6","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.eururo.2019.06.015","article-title":"Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights","volume":"76","author":"Carlo","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.path.2026.01.007_bib7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2013.50.8192","article-title":"Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management","volume":"32","author":"Shuch","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.path.2026.01.007_bib8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/PAP.0b013e318299b7c6","article-title":"Hereditary syndromes with associated renal neoplasia: a practical guide to histologic recognition in renal tumor resection specimens","volume":"20","author":"Przybycin","year":"2013","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.path.2026.01.007_bib9","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.path.2026.01.007_bib10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semcancer.2012.06.001","article-title":"The VHL\/HIF axis in clear cell renal carcinoma","volume":"23","author":"Shen","year":"2013","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"10.1016\/j.path.2026.01.007_bib11","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2015.08.007","article-title":"Hypoxia, hypoxia-inducible transcription factors, and renal cancer","volume":"69","author":"Sch\u00f6del","year":"2016","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.path.2026.01.007_bib12","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1016\/j.celrep.2017.02.074","article-title":"The SWI\/SNF protein PBRM1 restrains VHL-Loss-Driven Clear Cell Renal Cell carcinoma","volume":"18","author":"Nargund","year":"2017","journal-title":"Cell Rep"},{"issue":"6377","key":"10.1016\/j.path.2026.01.007_bib13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.path.2026.01.007_bib14","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Pena-Llopis","year":"2012","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.path.2026.01.007_bib15","first-page":"331","article-title":"Loss of SETD2 induces a metabolic switch in renal cell carcinoma cell lines toward enhanced oxidative phosphorylation","volume":"18","author":"Liu","year":"2019","journal-title":"J Proteome Res"},{"issue":"2","key":"10.1016\/j.path.2026.01.007_bib16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1470-2045(12)70584-3","article-title":"Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation","volume":"14","author":"Kapur","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.path.2026.01.007_bib17","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.cell.2018.03.057","article-title":"Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal","volume":"173","author":"Turajlic","year":"2018","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.path.2026.01.007_bib18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cell.2018.02.020","article-title":"Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal","volume":"173","author":"Mitchell","year":"2018","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.path.2026.01.007_bib19","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"NEJM"},{"issue":"6","key":"10.1016\/j.path.2026.01.007_bib20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ejhg.2010.175","article-title":"von Hippel-Lindau disease: a clinical and scientific review","volume":"19","author":"Maher","year":"2011","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.path.2026.01.007_bib21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2407-9-152","article-title":"High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas","volume":"9","author":"Yusenko","year":"2009","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.path.2026.01.007_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.2932","article-title":"Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status","volume":"225","author":"Bardella","year":"2011","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.path.2026.01.007_bib23","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10689-014-9735-2","article-title":"Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment","volume":"13","author":"Menko","year":"2014","journal-title":"Fam Cancer"},{"issue":"10","key":"10.1016\/j.path.2026.01.007_bib24","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1158\/1078-0432.CCR-20-4367","article-title":"Comprehensive molecular characterization and response to therapy in fumarate hydratase-deficient renal cell carcinoma","volume":"27","author":"Gleeson","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.path.2026.01.007_bib25","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1097\/PAS.0000000000000292","article-title":"Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients","volume":"38","author":"Gill","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.path.2026.01.007_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/humu.21136","article-title":"Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD","volume":"31","author":"Ricketts","year":"2010","journal-title":"Hum Mutat"},{"issue":"2","key":"10.1016\/j.path.2026.01.007_bib27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/his.13865","article-title":"Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity?","volume":"75","author":"Trpkov","year":"2019","journal-title":"Histopathology"},{"issue":"11","key":"10.1016\/j.path.2026.01.007_bib28","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1097\/PAS.0000000000000248","article-title":"Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients","volume":"38","author":"Guo","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.path.2026.01.007_bib29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/PAS.0000000000001170","article-title":"Somatic mutations of TSC2 or MTOR characterize a morphologically distinct subset of sporadic renal cell carcinoma with Eosinophilic and vacuolated cytoplasm","volume":"43","author":"Chen","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.path.2026.01.007_bib30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrurol.2014.162","article-title":"Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers","volume":"11","author":"Kauffman","year":"2014","journal-title":"Nat Rev Urol"},{"issue":"2","key":"10.1016\/j.path.2026.01.007_bib31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.semdp.2015.02.003","article-title":"MiT family translocation renal cell carcinoma","volume":"32","author":"Argani","year":"2015","journal-title":"Semin Diagn Pathol"},{"issue":"1","key":"10.1016\/j.path.2026.01.007_bib32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9440(10)61684-7","article-title":"Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents","volume":"159","author":"Argani","year":"2001","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.path.2026.01.007_bib33","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/PAS.0b013e31827e17cb","article-title":"TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum","volume":"37","author":"Rao","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.path.2026.01.007_bib34","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1158\/0008-5472.CAN-06-2855","article-title":"TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition","volume":"67","author":"Tsuda","year":"2007","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.path.2026.01.007_bib35","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/gcc.22346","article-title":"ALK-rearranged renal cell carcinomas in children","volume":"55","author":"Cajaiba","year":"2016","journal-title":"Genes, Chromosomes & Cancer"},{"issue":"11","key":"10.1016\/j.path.2026.01.007_bib36","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/modpathol.2012.107","article-title":"ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients","volume":"25","author":"Sukov","year":"2012","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.path.2026.01.007_bib37","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1078-0432.CCR-17-3296","article-title":"A model linking sickle cell hemoglobinopathies and SMARCB1 loss in renal medullary carcinoma","volume":"24","author":"Msaouel","year":"2018","journal-title":"Clinical cancerRes"},{"issue":"1","key":"10.1016\/j.path.2026.01.007_bib38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.eururo.2014.02.035","article-title":"ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma","volume":"66","author":"Brooks","year":"2014","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.path.2026.01.007_bib39","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1470-2045(15)70167-1","article-title":"A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies","volume":"16","author":"Rini","year":"2015","journal-title":"Lancet Oncol"},{"issue":"7492","key":"10.1016\/j.path.2026.01.007_bib40","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.path.2026.01.007_bib41","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"48","key":"10.1016\/j.path.2026.01.007_bib42","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1038\/onc.2009.280","article-title":"Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner","volume":"28","author":"di Martino","year":"2009","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.path.2026.01.007_bib43","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.2207","article-title":"FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer","volume":"213","author":"Tomlinson","year":"2007","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.path.2026.01.007_bib44","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/hmg\/dds486","article-title":"Oncogenic FGFR3 gene fusions in bladder cancer","volume":"22","author":"Williams","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.path.2026.01.007_bib45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.anndiagpath.2015.12.002","article-title":"Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications","volume":"21","author":"Kurtis","year":"2016","journal-title":"Ann Diagn Pathol"},{"issue":"2","key":"10.1016\/j.path.2026.01.007_bib46","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eururo.2013.08.052","article-title":"Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome","volume":"65","author":"Allory","year":"2014","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.path.2026.01.007_bib47","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1470-2045(05)70315-6","article-title":"P53 as a prognostic marker for bladder cancer: a meta-analysis and review","volume":"6","author":"Malats","year":"2005","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.path.2026.01.007_bib48","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1038\/sj.onc.1205304","article-title":"Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer","volume":"21","author":"Simon","year":"2002","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.path.2026.01.007_bib49","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.path.2026.01.007_bib50","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur Urol"},{"issue":"14","key":"10.1016\/j.path.2026.01.007_bib51","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-16-2520","article-title":"DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma","volume":"23","author":"Teo","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.path.2026.01.007_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013821","article-title":"FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy","volume":"5","author":"Kompier","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.path.2026.01.007_bib53","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.path.2026.01.007_bib54","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.path.2026.01.007_bib55","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sj\u00f6dahl","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.path.2026.01.007_bib56","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"NEJM"},{"key":"10.1016\/j.path.2026.01.007_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in bladder cancer: treatment landscape and future challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"6_suppl","key":"10.1016\/j.path.2026.01.007_bib59","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS583","volume":"41","author":"Vilaseca","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.path.2026.01.007_bib60","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.path.2026.01.007_bib61","series-title":"A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2)","author":"Ghatalia","year":"2025"},{"issue":"17","key":"10.1016\/j.path.2026.01.007_bib62","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","article-title":"Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers","volume":"36","author":"Teo","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.path.2026.01.007_bib63","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1078-0432.CCR-18-1001","article-title":"ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer","volume":"25","author":"Li","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.path.2026.01.007_bib64","first-page":"47","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-Expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Orthod"},{"issue":"12","key":"10.1016\/j.path.2026.01.007_bib65","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-Positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.path.2026.01.007_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1011885","article-title":"HER2 expression in urothelial carcinoma, a systematic literature review","volume":"12","author":"Scherrer","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.path.2026.01.007_bib67","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.eururo.2014.05.004","article-title":"A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling","volume":"66","author":"Klein","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.path.2026.01.007_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066855","article-title":"Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy","volume":"8","author":"Erho","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.path.2026.01.007_bib69","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1470-2045(10)70295-3","article-title":"Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.path.2026.01.007_bib70","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1158\/1078-0432.CCR-14-2603","article-title":"Development and clinical validation of an In Situ biopsy-based multimarker assay for risk stratification in prostate cancer","volume":"21","author":"Blume-Jensen","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.path.2026.01.007_bib71","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3390\/clinpract14020039","article-title":"Tissue-based genomic testing in prostate cancer: 10-year analysis of national trends on the use of Prolaris, Decipher, ProMark, and oncotype DX","volume":"14","author":"Bologna","year":"2024","journal-title":"Clin Pract"},{"issue":"7","key":"10.1016\/j.path.2026.01.007_bib72","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1097\/PAS.0000000000001450","article-title":"Report from the international Society of Urological Pathology (ISUP) consultation conference on molecular Pathology of urogenital cancers. I. Molecular biomarkers in prostate cancer","volume":"44","author":"Lotan","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.path.2026.01.007_bib73","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","article-title":"Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology","volume":"75","author":"Nuhn","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.path.2026.01.007_bib74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2217\/fon-2019-0745","article-title":"Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy","volume":"16","author":"Cimadamore","year":"2020","journal-title":"Future Oncol"},{"issue":"22","key":"10.1016\/j.path.2026.01.007_bib75","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"6 Suppl","key":"10.1016\/j.path.2026.01.007_bib76","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.2021.39.6_suppl.126","article-title":"Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound","volume":"39","author":"De Bono","year":"2021","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.path.2026.01.007_bib77","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.path.2026.01.007_bib78","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.3390\/cancers15092435","article-title":"Frequency of germline and somatic BRCA1 and BRCA2 mutations in prostate cancer: an updated systematic review and meta-analysis","volume":"15","author":"Valsecchi","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.path.2026.01.007_bib79","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-Repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.path.2026.01.007_bib80","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-Repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.path.2026.01.007_bib81","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","article-title":"Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study","volume":"26","author":"Abida","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"10398","key":"10.1016\/j.path.2026.01.007_bib82","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.path.2026.01.007_bib83","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.path.2026.01.007_bib84","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.euo.2024.09.013","volume":"8","author":"Clarke","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.path.2026.01.007_bib85","first-page":"LBA5006","article-title":"Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes","volume":"43","author":"Attard","year":"2025","journal-title":"J Clin Orthod"},{"issue":"9","key":"10.1016\/j.path.2026.01.007_bib86","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"ESMO Guidelines Committee. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.path.2026.01.007_bib87","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1177\/03008916251379317","article-title":"Liquid biopsy in prostate cancer: A multidisciplinary expert consensus statement","volume":"111","author":"Pepe","year":"2025","journal-title":"Tumori"},{"issue":"7","key":"10.1016\/j.path.2026.01.007_bib88","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.path.2026.01.007_bib89","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-20-4805","article-title":"Genomic analysis of circulating tumour DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms","volume":"27","author":"Tukachinsky","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.path.2026.01.007_bib90","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.3390\/ijms22115522","article-title":"Circulating tumour DNA testing for homology recombination repair genes in prostate cancer: from the lab to the clinic","volume":"22","author":"Cimadamore","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.path.2026.01.007_bib91","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1158\/1078-0432.CCR-22-0931","article-title":"Detection of BRCA1, BRCA2, and ATM alterations in matched tumour tissue and circulating tumour DNA in patients with prostate cancer screened in PROfound","volume":"29","author":"Chi","year":"2023","journal-title":"Clin Cancer Res"}],"container-title":["Surgical Pathology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918126000073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918126000073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:22:27Z","timestamp":1777947747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875918126000073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1875918126000073"],"URL":"https:\/\/doi.org\/10.1016\/j.path.2026.01.007","relation":{},"ISSN":["1875-9181"],"issn-type":[{"value":"1875-9181","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Pathology of Genitourinary Tumors","name":"articletitle","label":"Article Title"},{"value":"Surgical Pathology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.path.2026.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}